That very one.
Now rather than ignoring it, maybe a bit of reflection that the failure to get a CEO, the constant talk of partnership engagement by the Chairman, the lack of transparency of how much they burned due to the FDA delays when they are on record they set themselves up as "risk on" for trial commencement before IND submission, and the failure to raise at a higher share price makes this capital raise very large, and very ugly - akin to the last one where they raised at the extreme lows.
research reports and media, page-2750
-
- There are more pages in this discussion • 1,679 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.31M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.0¢ | 25.0¢ | $707.9K | 2.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 67996 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9614 | 1 |
View Market Depth
| Last trade - 12.40pm 18/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |